review perform stock coverag
insur hcit bio-technolog sub-sector
review coverag healthcare/lif scienc sector
review perform stock coverag insur hcit bio-technolog
healthcar sector xlv outperform sector growth year
health care sector perform led insur sector saw huge declin pharma
biotechnolog sector stock like merck end year double-digit gain
review perform healthcar space insur hcit
stock coverag
insur perform sector xh flat
outperform sector within healthcar sector sign-up feder health insur
market place fallen chang made trump administr scale back
health-car law took hold legal challeng left fate afford act question
led declin stock price insur compani decemb stock
perform neg year perform well return
recommend buy rate stock expect compani abl gener
single-digit growth revenu
healthcar innov taken hold pharmaceut space compani
offer technology-en product servic prescrib pharmacist healthcar
organ pharmaci cost manag medic risk manag risk adjust
initi coverag sector stock perform
strong return respect
pharmaceut pharmaceut sector index xph declin due
issu regard rise drug price mani pharmaceut migrat focu toward
biosimilar larg molecul biolog due lower project expenditur quicker return
firm concentr orphan drug slightli easier time obtain fda
approv longer patent live stock like merck soar due key
product keytruda got mani approv gener huge sale merck soar
due acquisit made compani
among market oversold sector declin nearli
soar due strong perform busi led growth
emerg market celgen stock tumbl acquir bristol-my
squibb januari biotech stock show decent growth year other
tank
jan
jan
tp
reflect strong oper perform help growth
perform well stock give almost
return stock price show huge growth
june decemb surg
high stock lost past month
time medic sector lost
perform on-going posit momentum across
busi launch act wise engag
result strong growth number
member use tool platform expect
deliv strong growth futur provid healthcar
solut consum
forecast expect perform well
tri differenti competitor
innov also tri battl rise drug price
implement new system pharmaci benefit manag
expect stock reach deriv
tp ep along earn multipl
estim top line growth
base mrq
compani nameanthem inc tickerantmstock ratingbuyunchangedindustri viewoverweightpositivepric dec week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth price coverag iew| januari
growth acceler combin express script
stock perform declin stock
dip low march
announc express script acquisit stock
surg high januari
strong result howev stock surg
decemb declin end month
deliv strong oper result substanti
revenu earn growth recent quarter due
growth global busi
recent complet acquisit express script
whose pharmaci benefit busi health insur
busi help control drug price cost larg extent
one biggest compon soar medic cost
forecast expect strong perform
due acquisit express script strong double-digit
growth intern market sinc past year expect
stock reach deriv estim base
forward price-to-earnings multipl ep
expect top-lin revenu grow
base mrq
compani namecigna corporationtickercistock ratingbuyunchangedindustri viewoverweightpositivepric dec week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth price coverag iew| januari
strong growth medicar advantag plan expect
stock gave return surg
week high novemb quarter
result stock declin month
decemb low februari
deliv strong perform
growth revenu growth due increas
medicar advantag membership member
forecast contract rate
member rate contract
offer repres compani
membership juli estim tp
base forward price-to-earnings multipl adjust ep
estim revenu growth
base mrq
compani namehumana inc tickerhumstock ratingbuyunchangedindustri viewoverweightpositivepric dec week week volum volum p/en/adilut ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth price coverag iew| januari
continu strong well-diversifi perform across enterpris
stock price gave return show
upward trend till decemb stock surg
declin decemb
perform well growth revenu
recent quarter growth across busi
optum care serv
peopl way organ growth expand presenc
forecast expect perform well
continu appli capit busi
ventur invest organ develop strengthen
offer custom diversifi enterpris
expect stock reach deriv tp
ep forward look pe
expect top-lin revenu growth
base mrq
compani nameunitedhealth group tickerunhstock ratingholddowngradeindustri viewoverweightpositivepric week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth price coverag iew| januari
track perform key metric expect rang
cerner stock price declin dip
decemb high stock
januari
perform lower end guidanc
due lower expect softwar technolog resal
recent collabor covermym
integr patient specif inform electron health
record provid review prescript price inform
patient point care
forecast opportun grow healthcar
potenti perform better come year
estim tp base forward price-to-earnings multipl
adjust ep expect top line
growth
base mrq
compani namecern corporationtickercernstock ratingbuyunchangedindustri viewoverweightpositivepric dec week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth price coverag iew| januari
sold interest netsmart busi
stock perform declin stock
dip low decemb
week high januari
allscript announc veradigm new brand
allscript payer life scienc divis veradigm
integr data system servic busi combin
data-driven clinic insight action tool clinic
workflow research analyt media share price
allscript increas ytd howev stock lost
compar industri declin
decreas year time
recent collabor microsoft corpor
explor innov technolog enhanc clinic
research design clinic studi improv research
process allscript expand cloud-bas electron health
record ehr platform new technolog stock
price increas announc
forecast howev still loss expect
revenu grow base perform
keen observ growth book near
futur estim tp base forward price-to-earnings
multipl ep
base mrq
compani nameallscript healthcar solutionstickermdrxstock ratingbuyunchangedindustri viewoverweightpositivepric dec week week volum volum ttm n/ap/ ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth yoy n/acrispideaakansha price coverag iew| januari
clinic commerci vault continu drive revenu out-performance
veeva system provid cloud-bas softwar solut
global life scienc industri stun year
stock price gain period jan
jan stock grew rate
upgrad strength busi perform
stock high low
stock price declin nearli sinc oct
reach high sep due sell-off
global market
saw great momentum multipl vault product
categori coupl steadi progress grow
leadership posit commerci cloud vault
driven out-performance clinic commerci
forecast maintain buy rate
tp estim tp base
ev/revenu time expect revenu
grow respect
estim adjust ep
expect forward price-to-earnings
base mrq
compani nameveeva system inc class atickerveevstock ratingbuyunchangedindustri viewoverweightpositivepric jan week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth coverag iew| januari
recent acquisit invest lead growth futur
stock perform strong past one year
gave return stock surg
septemb low stock
januari howev stock shown declin
high current trade around
deliv double-digit growth revenu
increas margin announc technolog
strategi design har
power trhc core technolog medwis eirenerx
leverag technolog brought compani
acquisit like sinfoniarx rxcompanion
meditur eclus technolog electron health
record health plan manag
forecast expect perform well due
acquisit made creat growth
opportun compani expect stock reach
base ev/revenu time expect top-
line revenu grow
base mrq
pricecompani nametabula rasa tickertrhcstock ratingbuyunchangedindustri viewoverweightpositivepric jan week week volum volum ttm n/ap/ ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth coverag iew| januari
continu invest busi led growth
agil stock price declin
volatil high decemb
low june beta
valu agil compar whole
industri show agil volatil
agil deliv strong perform due
continu growth end-market china well agil
acquir prozym inc young
scientif co ltd expand busi also
launch new product year
forecast expect agil perform well
top-line revenu expect grow
maintain tp
well stock perform neg tp
base forward price-to-earnings multipl adjust ep
base mrq
pricecompani inc tickerastock ratingbuyunchangedindustri viewoverweightpositivepric jan week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth coverag iew| januari
repatha prolia futur growth driver
stock gave return surg
septemb low stock
april stock dip
decemb current show upward trend
perform year strong due
volum growth new recent launch product
outpac declin matur brand like enbrel
neulasta brand suffer y/i declin due
increas competit market lower drug price
forecast expect deliv strong
perform due newli launch product
includ repatha prolia aimovig recommend hold
rate tp tp base
forward price-to-earnings multipl adjust ep
expect revenu grow base
perform
base mrq
compani nameamgen inc tickeramgnstock ratingholdunchangedindustri viewoverweightpositivepric dec week week volum volum p/en/adilut ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth price coverag iew| januari
becton dickinson co
histor year success complet acquisit bard
stock price show upward trend till octob
surg high howev stock
price later declin went low
decemb stock price declin
strong perform due acquisit
bard revenu increas due
growth across segment also saw growth asia
pacif latin america ema also receiv approv
fda bd enter viral panel
bd acquir tva medic advanc leadership solut
kidney diseas also launch mani new product
applic help hospit system identifi drug
forecast expect strong perform
well due acquisit bard new
product launch made recommend buy
rate tp base forward
price-to-earnings multipl adjust ep expect
revenu grow
base mrq
compani namebecton dickinson tickerbdxstock ratingbuyunchangedindustri viewoverweightpositivepric dec week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth yoy n/acrispideaakansha price coverag iew| januari
track desir growth implement correct strategi
stock price declin
low april stock surg
high june later show
downward trend dip decemb
deliv strong revenu due growth
spinraza biosimilar busi continu
advanc pipelin beyond industri lead portfolio
ms alzheim launch imraldi adalimumab
biosimilar referenc humira imraldi avail
built reput treat ms overal sale
ms franchis slip tecfidera continu
enjoy modest growth could new ms drug
pipelin fda approv vumer
forecast expect revenu grow
base perform advanc
pipelin expect stock would reach
base adjust ep forward price-to-earnings multipl
base mrq
pricecompani namebiogen inc tickerbiibstock ratingbuyunchangedindustri viewoverweightpositivepric week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth coverag iew| januari
whole lot acquisit enhanc long-term growth profil
stock perform strong year
gave return show upward trend
surg octob low
februari
continu deliv strong perform
quarter led growth emerg market also
launch new product contribut growth
busi
medsurg led way growth rhythm
neuro grew cardiovascular sale increas
organ basi recent quarter emerg market sale
grew oper led strong perform china
latin america
forecast expect revenu grow
base perform advanc pipelin
expect stock would reach base
forward price-to-earnings multipl adjust ep
base mrq
pricecompani tickerbsxstock ratingbuyunchangedindustri viewoverweightpositivepric week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth coverag iew| januari
strong volum growth across brand
celgen stock price volatil throughout year
declin high stock
januari low stock
decemb
celgen stock price shown declin trend sinc
decemb due drug meet end-
point studi sinc stock
abl recov howev celgen report strong growth
revenu earn
growth revenu celgen due growth
volum across brand revlimid pomalyst
/imnovid otezla abraxan januari
bristol-my squibb announc acquir celgen
acquisit complet
forecast expect celgen revenu grow
base advanc pipelin
recommend buy rate stock tp
base forward price-to-earnings multipl adjust ep
base mrq
compani namecelgen corporationtickercelgstock ratingbuyupgradeindustri viewoverweightpositivepric week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth price coverag iew| januari
strong revenu growth continu margin expans
perform well return year
howev stock show huge fluctuat year
surg decemb
low stock februari
deliv strong growth achiev
combin new product innov strong
commerci execut strateg acquisit
increas exposur attract end market
elev demand dhr popular product line
includ dxh analyz dxa genexpert edg
pelori tissu process like continu
bolster segment sale
forecast continu demand innov
product led growth dhr revenu
solid core revenu growth benefit effect
implement danah busi system db
well improv oper incom like boost dhr
profit expect revenu grow
expect stock price reach
base mrq
compani namedanah corporationtickerdhrstock ratingbuyunchangedindustri viewoverweightpositivepric oct week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth price coverag iew| januari
hcv product sale continu declin deterior overal growth
stock perform declin dip
decemb stock high
januari show downward trend
year
gild perform declin due continu
declin one best sell drug product hcv
product hcv product revenu declin due
emerg new competit threat abbvi
gilead latest hiv medicin biktarvi appear
counteract on-going declin hcv sale biktarvi
set record success hiv launch
gilead anoth promis asset filgotinib
develop collabor galapago nv varieti
autoimmun condit declar posit result
base mrq
forecast expect revenu declin
base perform expect stock
price would reach base forward price-to-earnings multipl
adjust ep
compani namegilead scienc inc tickergildstock ratingsellunchangedindustri viewoverweightpositivepric week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth price coverag iew| januari
growth led diabet segment sever new launch
perform well return stock
year high stock
septemb low march
howev stock show upward trend till novemb
due strong perform quarter
variou launch compani
oper gener free cash flow
past year give plenti breath room
rais dividend payment execut acquisit help
solidifi posit key market
enter robot-assist surgeri market last year
current launch system help surgeon
fix bad back line spinal repair product
probabl launch next-gener stent
stroke patient help compani maintain lead
cardiovascular space
forecast highli posit foray
stand-alone continu glucos monitor cgm
market guardian connect expect stock
reach expect growth revenu
base mrq
compani namemedtron plc ordinari sharestickermdtstock ratingbuyunchangedindustri viewoverweightpositivepric jan week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth price thermo fisher scientif
strong growth emerg market remain competit advantag
tmo stock perform well gave return
stock show upward trend surg
decemb low februari
tmo increas scale asia-pacif emerg market
remain competit advantag compani saw
strong perform china growth
launch number new instrument life
scienc specialti diagnost invitrogen evo
isq em mass spectromet phadia allergi
autoimmun system europ
forecast expect revenu grow
recommend buy rate stock expect
stock reach base forward price-to-earnings multipl
adjust ep
base mrq
pricecompani namethermo fisher tickertmostock ratingbuyunchangedindustri viewoverweightpositivepric week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth coverag iew| januari
total revenu increas y/i perform
abbott stock perform strong due
strong growth busi stock volatil till
august later show upward trend surg
decemb low stock
februari
abbott perform strong due growth
across segment strong pipelin receiv
approv product alongsid achiev clinic trial
mileston last quarter
abbott freestyl libr achiev rapid market uptak
y/i increas sale expect
continu gain product
forecast expect perform well due
strong product pipelin recent present
posit clinic result coapt studi support
efficaci mitraclip expect boost uptak
product top-lin contribut expect stock
reach revenu growth expect
base mrq
compani nameabbott laboratoriestickerabtstock ratingbuyunchangedindustri viewoverweightpositivepric week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth price coverag iew| januari
imbruvica venclexta key growth driver
abbvi stock perform declin
dip novemb stock surg
januari downward trend sinc
march due coupl pipelin setback well
concern biosimilar competit blockbust drug
humira eu
rova-t ad portfolio follow
acquisit stemcentrx june failur triniti
clinic hold taho rais skeptic rova-
ts potenti brought question viabil
deep pipelin consist sever interest
late-stag candid success seek
approv product like imbruvica venclexta
mavyret contribut growth
busi expect two approv
gener revenu compani
forecast abbvi humira perform well
base strong demand trend despit new competit
competit europ erod humira revenu
expect growth revenu expect
stock reach base forward price-to-earnings multipl
adjust ep
base mrq
compani nameabbvi inc tickerabbvstock ratingbuyunchangedindustri viewoverweightpositivepric dec week week volum volum mrq n/aforward ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth price coverag iew| januari
report organ growth across segment
bhc stock price volatil surg
octob declin
low march
bhc revenu grow organ sinc last quarter
also reduc debt sinc
top product bhc grew organ aggreg
bhc gener revenu bausch
lomb/intern segment salix segment
bhc lot new product activ pipelin
includ launch lucemyra august sihi daili
lens launch japan septemb plenvu
also launch septemb bhc also success launch
lumifi achiev weekli market share
red reliev categori
forecast expect bhc revenu increas
due new product launch bhc yet
receiv approv product would
contribut growth busi recommend
sell rate stock tp base
perform estim tp base forward
price-to-earnings multipl adjust ep
base mrq
compani namebausch health compani inc tickerbhcstock ratingsellunchangedindustri viewoverweightpositivepric jan week week volum volum ttm n/ap/ ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth yoy n/acrispideaakansha price coverag iew| januari
relaunch johnson babi product strengthen busi
stock price saw huge fluctuat declin
year high stock
decemb later declin due
alleg made manag regard safeti issu
jnj talcum powder stock low
may due claim made jnj hip implant
perform strong last quarter due
market growth pharmaceut segment strong sale
momentum consum segment continu growth
forecast expect revenu grow
base perform past quarter jnj pharma
sector led growth past due growth oncolog
product recommend hold rate tp
tp base forward price-to-earnings multipl
adjust ep
base mrq
pricecompani namejohnson johnsontickerjnjstock ratingholdunchangedindustri viewoverweightpositivepric week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth coverag iew| januari
merck stock gave strong perform return
stock high decemb
low april
continu success lead drug keytruda main
driver behind stock impress perform last year
short span time keytruda becom merck
largest product alreadi approv use sever
indic across eight differ tumor type unit
state gain approv market global
keytruda sale gain particularli strong momentum
indic first-lin lung cancer anti-
approv set monotherapi well
forecast strong perform support
strong quarterli result posit pipelin regulatori
updat merck look well pois continu momentum
expect revenu grow
recommend buy rate stock tp
tp base forward price-to-earnings multipl adjust ep
base mrq
compani namemerck compani tickermrkstock ratingbuyunchangedindustri viewoverweightpositivepric week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth yoy n/acrispideaakansha price coverag iew| januari
margin accret growth driven innov medicin divis
novarti stock price gave return stock
show huge fluctuat throughout year
high stock januari
low june compani announc spin-
alcon busi
novartiss effort turnaround busi
impress given loss exclus key drug nv
made acquisit develop pipelin promis
area novarti restructur busi plan
focu becom core drug-focus compani power
data digit technolog
forecast expect strong perform new drug
approv innov therapi boost busi compani
expect revenu grow base
acquisit done nv advanc pipelin
recommend buy rate nv tp base
forward price-to-earnings multipl adjust ep
base mrq
pricecompani namearti agtickernvsstock ratingbuyunchangedindustri viewoverweightpositivepric week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth coverag iew| januari
posit deliv new medicin acceler growth enhanc sharehold valu tp
pfizer stock gave strong perform growth
stock price stock show upward
trend due acquisit made past
year gener revenu compani
also approv receiv fda product
high stock decemb
low stock februari
revenu grew narrow
revenu guidanc rang due
weaker-than-expect perform essenti
segment on-going product shortag legaci
hospira steril inject busi unfavor foreign
howev program blockbust potenti
come year face challeng due
continu neg impact drug lose
exclus focu bring phase phase
asset pipelin target therapeut area
base mrq
forecast expect revenu grow
base pipelin perform
recommend buy rate tp
base forward price-to-earnings multipl adjust ep
compani namepf inc tickerpfestock ratingbuyunchangedindustri viewoverweightpositivepric dec week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth price coverag iew| januari
focus specialti emerg market
sanofi stock show huge fluctuat due
declin perform stock gave
return year low stock
may high stock
januari
sanofi growth driven contribut
bioverativ ablynx deal improv vaccin sale
decreas impact patent expir compani
specialti segment particularli strong foot
recent fda approv new drug libtayo cablivi
dupix second indic asthma
sanofi diabet unit sale declin due suppli
constraint year compens slump sale
diabet unit sanofi busi multipl front
year complet take-over deal worth
expand oncolog speed cost-cut effort
forecast expect revenu grow
base perform recommend hold rate
stock tp base forward price-to-earnings multipl
adjust ep
base mrq
compani namesanofi american depositari shartickersnystock ratingholdunchangedindustri viewoverweightpositivepric oct week week lowerroravg volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth price coverag iew| januari
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
